Exact Mass: 313.0811006
Exact Mass Matches: 313.0811006
Found 87 metabolites which its exact mass value is equals to given mass value 313.0811006,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Hexaconazole
C14H17Cl2N3O (313.07486120000004)
CONFIDENCE standard compound; INTERNAL_ID 1269; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9950; ORIGINAL_PRECURSOR_SCAN_NO 9948 CONFIDENCE standard compound; INTERNAL_ID 1269; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9938; ORIGINAL_PRECURSOR_SCAN_NO 9937 CONFIDENCE standard compound; INTERNAL_ID 1269; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9900; ORIGINAL_PRECURSOR_SCAN_NO 9899 CONFIDENCE standard compound; INTERNAL_ID 1269; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9947; ORIGINAL_PRECURSOR_SCAN_NO 9942 CONFIDENCE standard compound; INTERNAL_ID 1269; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9912; ORIGINAL_PRECURSOR_SCAN_NO 9911 CONFIDENCE standard compound; INTERNAL_ID 1269; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9988; ORIGINAL_PRECURSOR_SCAN_NO 9986
Flunitrazepam
A benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug. [PubChem] N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CD - Benzodiazepine derivatives D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
(S)-5'-Deoxy-5'-(methylsulfinyl)adenosine
C11H15N5O4S (313.08447100000006)
(S)-5-Deoxy-5-(methylsulfinyl)adenosine is found in mushrooms. (S)-5-Deoxy-5-(methylsulfinyl)adenosine is produced by Ganoderma lucidum (reishi). Production by Ganoderma lucidum (reishi). (R)-5-Deoxy-5-(methylsulfinyl)adenosine is found in mushrooms.
2-Methylthioadenosine
C11H15N5O4S (313.08447100000006)
Flubendazole
P - Antiparasitic products, insecticides and repellents > P02 - Anthelmintics > P02C - Antinematodal agents > P02CA - Benzimidazole derivatives D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites[1][2].
Flubendazole
P - Antiparasitic products, insecticides and repellents > P02 - Anthelmintics > P02C - Antinematodal agents > P02CA - Benzimidazole derivatives D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 3659 CONFIDENCE standard compound; INTERNAL_ID 1163 CONFIDENCE standard compound; INTERNAL_ID 1063 Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites[1][2].
4-Amino-benzoyl-glucuronid|4-Amino-benzoylglucuronid|<1-(4-Amino-benzoyl)-glucosid>-uronsaeure
O1-(2-carbamoyl-phenyl)-beta-D-glucopyranuronic acid|O1-(2-Carbamoyl-phenyl)-beta-D-glucopyranuronsaeure|Salicylamide glucuronide
O1-(3-carbamoyl-phenyl)-beta-D-glucopyranuronic acid|O1-(3-Carbamoyl-phenyl)-beta-D-glucopyranuronsaeure
O1-(4-carbamoyl-phenyl)-beta-D-glucopyranuronic acid|O1-(4-Carbamoyl-phenyl)-beta-D-glucopyranuronsaeure
flunitrazepam
N - Nervous system > N05 - Psycholeptics > N05C - Hypnotics and sedatives > N05CD - Benzodiazepine derivatives D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 3681 CONFIDENCE standard compound; INTERNAL_ID 1595
2-Methylthioadenosine; LC-tDDA; CE10
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; LC-tDDA; CE20
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; LC-tDDA; CE30
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; LC-tDDA; CE40
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; AIF; 0eV; CorrDec
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; AIF; 30eV; CorrDec
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; AIF; 10eV; CorrDec
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; AIF; 0eV; MS2Dec
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; AIF; 10eV; MS2Dec
C11H15N5O4S (313.08447100000006)
2-Methylthioadenosine; AIF; 30eV; MS2Dec
C11H15N5O4S (313.08447100000006)
5'-Deoxy-5'-(methylsulfinyl)adenosine, 9CI
C11H15N5O4S (313.08447100000006)
5-[(4-METHOXYPHENOXY)METHYL]-4-PHENYL-4H-1,2,4-TRIAZOLE-3-THIOL
3-[[1-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YL)ETHYL]AMINO]-1-PROPANOL
C14H17Cl2N3O (313.07486120000004)
3-(CHLOROPHENYLMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID ETHYL ESTER
(2-Methyl-4-phenylquinolin-3-yl)acetic acid hydrochloride
1-Naphthalenesulfonicacid, 8-[(4-methylphenyl)amino]-
2-(Fluoroacetyl)-3-(2-methylphenyl)-6-nitroquinazolin-4(3H)-one
Amezinium metilsulfate
C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors Amezinium metilsulfate has multiple mechanisms, including stimulation of alpha and beta-1 receptors and inhibition ofnoradrenaline and tyramine uptake. Target: alpha and beta-1 receptors Amezinium metilsulfate is a sympathomimetic drug used for the treatment of low blood pressure. Cardiovascular effects of the new sympathomimetic Amezinium metilsulphate are investigated in 25 patients compared with a control group (n = 25). During spinal/epidural anaesthesia 5 mg amezinium is given i.v. if blood pressure dropped greater than 20 mmHg. from starting-point. A significant recovery of blood pressure (epidural anaesthesia: syst 21\%, diast 9\%; spinal anaesthesia: syst 13\%, diast 6.6\%) and a decrease in heart rate (6.8\% resp. 4,5\%) are thought due to peripheral vasoconstriction. Amezinium proves a stimulating drug for alpha- and beta 1-receptors by stabilising the systemic blood pressure in spinal/epidural anaesthesia.
2-Methyl-5-{3-[4-(methylsulfonyl)phenyl]-2-furyl}pyridine
1-(3,4-Dimethylphenyl)-3-(2-pyrimidinylthio)pyrrolidine-2,5-dione
6-(Hydroxyethyldithio)-8-(aminomethylthio)octanoic acid
6-(2-carbamoylphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid
3-(4-Morpholin-4-ylthieno[3,2-d]pyrimidin-2-yl)phenol
3,5-Dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-7-methoxychromenium
2-[[(2R)-2-amino-3-[(4-nitrophenyl)methylsulfanyl]propanoyl]amino]acetic acid
N-[[[(2-methylphenyl)-oxomethyl]hydrazo]-sulfanylidenemethyl]benzamide
2-methyl-N-[(5-nitro-2-furanyl)methylideneamino]-3-imidazo[1,2-a]pyridinecarboxamide
N-[1-[(4-chlorophenyl)methyl]-4-pyrazolyl]-2-pyrazinecarboxamide
1-(4-Methylphenyl)sulfonyl-4-phenyl-3-pyrazolamine
N-(4-aminobutyl)-5-chloronaphthalene-2-sulfonamide(1+)
3-[(6-Chloro-2-phenyl-1-benzopyran-4-ylidene)amino]-1-propanol
[(2S)-2-[(2R)-2-[[(2R)-2-azaniumylpropanoyl]amino]propanoyl]oxy-3-hydroxypropyl] phosphate
C9H18N2O8P- (313.08007380000004)
(S)-5-Deoxy-5-(methylsulfinyl)adenosine
C11H15N5O4S (313.08447100000006)
5-Deoxy-5-(methylsulfinyl)adenosine
C11H15N5O4S (313.08447100000006)
A member of the class of adenosines obtained by replacement of the 5-hydroxy group of adenosine by a methylsulfinyl group.
PNB-001
PNB-001 is an orally active CCK2 selective ligand and antagonist. PNB-001 has anti-inflammatory and analgesic activities[1].
(2r,3r,4s,5s)-2-(6-aminopurin-9-yl)-5-(methanesulfinylmethyl)oxolane-3,4-diol
C11H15N5O4S (313.08447100000006)
2-[(2-hydroxy-1,3-benzoxazol-6-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
2-acetyl-n-[2-(1h-indol-3-yl)ethyl]-1,3-thiazole-4-carboximidic acid
(2s,3r,4s,5s,6r)-2-[(2-hydroxy-1,3-benzoxazol-6-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
5,4'-dihydroxyl-6,7-dimethoxyl-8-c-[β-d-xylo-copyranosyl-(1→2)]-β-d-glucopyranosylflavone
C10H17ClFN3O5 (313.08407139999997)
{"Ingredient_id": "HBIN011052","Ingredient_name": "5,4'-dihydroxyl-6,7-dimethoxyl-8-c-[\u03b2-d-xylo-copyranosyl-(1\u21922)]-\u03b2-d-glucopyranosylflavone","Alias": "NA","Ingredient_formula": "C10H17ClFN3O5","Ingredient_Smile": "CC(C(=O)O)NC(=O)C(CCC(C(C(=O)O)N)(F)Cl)N","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "5948","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-[(2-hydroxy-1,3-benzoxazol-5-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(2s)-2-{[hydroxy(4-hydroxy-3,5-dimethoxyphenyl)methylidene]amino}butanedioic acid
5-methyl-5,10,20-triazapentacyclo[11.7.1.0²,⁷.0⁹,²¹.0¹⁴,¹⁹]henicosa-1(20),2(7),3,9,11,13(21),14(19),15,17-nonaene-6,8-dione
(2s,3r,4s,5s,6r)-2-[(2-hydroxy-1,3-benzoxazol-5-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3r,4s,5s)-2-(6-aminopurin-9-yl)-5-[(s)-methanesulfinylmethyl]oxolane-3,4-diol
C11H15N5O4S (313.08447100000006)